Overview

The Quadruple Test is a vital prenatal screening offered to pregnant women, typically during their second trimester. This diagnostic tool is designed to evaluate the likelihood of a foetus having specific chromosomal abnormalities, including Down’s syndrome (trisomy 21), Edwards’ syndrome (trisomy 18), and neural tube defects. Performed between the 14th and 20th weeks of pregnancy, we use this test to measure four key substances in the mother’s blood: Alpha-fetoprotein (AFP), Human chorionic gonadotropin (hCG), Inhibin A, and Estriol.

We prioritize the Quadruple Test due to its significant accuracy in detecting potential foetal abnormalities. Its reliability can be influenced by factors such as the mother’s age, weight, and diabetic status, as well as the gestational age of the foetus. While the Quadruple Test provides valuable insights, it is essential to note that it is a screening test, not a diagnostic test. It assesses the risk but does not definitively diagnose any condition. If abnormal levels are detected, we may recommend further diagnostic procedures, like amniocentesis or chorionic villus sampling (CVS).